Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $242.50 short put and a strike $237.50 long put offers a potential 12.36% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $242.50 by expiration. The full premium credit of $0.55 would be kept by the premium seller. The risk of $4.45 would be incurred if the stock dropped below the $237.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Valeant: Out of the Frying Pan, Into the Fire
Tue, 27 Jun 2017 18:02:00 +0000
Shares of Valeant Pharmaceuticals International (VRX) spiked yesterday on speculation regarding a possible debt-to-equity swap by the troubled drug maker. Wells Fargo analyst David Maris weighed in on the notion today, arguing that even if a swap does happen, it does not repair poor business trends or the increasingly unlikelihood that Valeant can deliver the strong earnings growth promised by consensus forecasts. As Maris writes: Based on our experience and feedback from our high yield debt analyst, we think that most debt holders do not have the ability or interest to take cross structure risk.
Bill Ackman's Big Triumph Becomes His Big Problem
Tue, 27 Jun 2017 13:51:44 +0000
One of the activist investor's greatest deals is under legal attack. There's no easy way out.
Allergan Introduces REFRESH OPTIVE® MEGA-3 Enhanced with Flaxseed Oil, Latest Innovation in the REFRESH® Portfolio
Tue, 27 Jun 2017 12:00:00 +0000
New Offering from REFRESH®, Number One Doctor Recommended Brand of Artificial Tears(1), Restores Lipid Layer While Bringing Hydration to All Three Layers of Tear Film Damaged by Dry Eye DUBLIN , June 27, …
Dillard's Is One of the Best Long-Term Investments in Retail, Doug Kass Says
Mon, 26 Jun 2017 23:54:00 +0000
Doug Kass shares his thoughts on his Allergan profit and discussing adding Dillard's to his list.
Valeant Pharma: A Debt Swap?
Mon, 26 Jun 2017 18:17:00 +0000
Why are shares of Valeant Pharmaceuticals International (VRX) rising and does the market have it right? According to Evercore ISI analyst Umer Raffat, anytime the market receives a signal of some sort that the embattled drug maker has value beyond its pile of debt, the stock price rises and short sellers cover their positions. Today, a 7.8% spike in Valeant’s share price is linked to speculation that a debt-to-equity swap could be on the horizon, Raffat says.
Related Posts
Also on Market Tamer…
Follow Us on Facebook